168 related articles for article (PubMed ID: 38136388)
1. Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positive Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms.
Wang J; Su X; Jiang L; Boudreau MW; Chatkewitz LE; Kilgore JA; Zahid KR; Williams NS; Chen Y; Liu S; Hergenrother PJ; Huang X
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136388
[TBL] [Abstract][Full Text] [Related]
2. IP-DNQ induces mitochondrial dysfunction and G2/M phase cell cycle arrest to selectively kill NQO1-positive pancreatic cancer cells.
Jiang L; Liu Y; Tumbath S; Boudreau MW; Chatkewitz LE; Wang J; Su X; Zahid KR; Li K; Chen Y; Yang K; Hergenrother PJ; Huang X
Antioxid Redox Signal; 2023 Nov; ():. PubMed ID: 37950707
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.
Lundberg AP; Francis JM; Pajak M; Parkinson EI; Wycislo KL; Rosol TJ; Brown ME; London CA; Dirikolu L; Hergenrother PJ; Fan TM
Invest New Drugs; 2017 Apr; 35(2):134-144. PubMed ID: 27975234
[TBL] [Abstract][Full Text] [Related]
4. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
5. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
6. Detecting Attomolar DNA-Damaging Anticancer Drug Activity in Cell Lysates with Electrochemical DNA Devices.
Wettasinghe AP; Singh N; Starcher CL; DiTusa CC; Ishak-Boushaki Z; Kahanda D; McMullen R; Motea EA; Slinker JD
ACS Sens; 2021 Jul; 6(7):2622-2629. PubMed ID: 34156840
[TBL] [Abstract][Full Text] [Related]
7. Distinct responses of compartmentalized glutathione redox potentials to pharmacologic quinones targeting NQO1.
Kolossov VL; Ponnuraj N; Beaudoin JN; Leslie MT; Kenis PJ; Gaskins HR
Biochem Biophys Res Commun; 2017 Jan; 483(1):680-686. PubMed ID: 27986568
[TBL] [Abstract][Full Text] [Related]
8. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
9. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
10. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics.
Parkinson EI; Hergenrother PJ
Acc Chem Res; 2015 Oct; 48(10):2715-23. PubMed ID: 26444384
[TBL] [Abstract][Full Text] [Related]
11. β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation.
Zhao W; Jiang L; Fang T; Fang F; Liu Y; Zhao Y; You Y; Zhou H; Su X; Wang J; Liu S; Chen Y; Wan J; Huang X
Front Oncol; 2021; 11():747282. PubMed ID: 34676172
[TBL] [Abstract][Full Text] [Related]
12. NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.
Li LS; Reddy S; Lin ZH; Liu S; Park H; Chun SG; Bornmann WG; Thibodeaux J; Yan J; Chakrabarti G; Xie XJ; Sumer BD; Boothman DA; Yordy JS
Mol Cancer Ther; 2016 Jul; 15(7):1757-67. PubMed ID: 27196777
[TBL] [Abstract][Full Text] [Related]
13. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
[TBL] [Abstract][Full Text] [Related]
14. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
15. Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer.
Starcher CL; Pay SL; Singh N; Yeh IJ; Bhandare SB; Su X; Huang X; Bey EA; Motea EA; Boothman DA
Front Oncol; 2020; 10():1575. PubMed ID: 32974194
[TBL] [Abstract][Full Text] [Related]
16. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
17. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
18. Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer.
Dou L; Liu H; Wang K; Liu J; Liu L; Ye J; Wang R; Deng H; Qian F
J Control Release; 2022 Sep; 349():876-889. PubMed ID: 35907592
[TBL] [Abstract][Full Text] [Related]
19. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
20. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
